Brokerages Expect American Renal Associates Holdings Inc (ARA) Will Post Quarterly Sales of $217.10 Million

Wall Street brokerages expect American Renal Associates Holdings Inc (NYSE:ARA) to report $217.10 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for American Renal Associates’ earnings. The lowest sales estimate is $217.00 million and the highest is $217.20 million. American Renal Associates posted sales of $194.38 million in the same quarter last year, which suggests a positive year over year growth rate of 11.7%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, March 5th.

On average, analysts expect that American Renal Associates will report full year sales of $840.05 million for the current financial year, with estimates ranging from $840.00 million to $840.10 million. For the next year, analysts forecast that the firm will post sales of $919.00 million, with estimates ranging from $910.00 million to $928.00 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for American Renal Associates.

American Renal Associates (NYSE:ARA) last announced its quarterly earnings data on Thursday, November 8th. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.06. American Renal Associates had a negative net margin of 1.81% and a positive return on equity of 22.30%. The company had revenue of $211.02 million during the quarter, compared to analysts’ expectations of $217.15 million. During the same quarter in the prior year, the company earned $0.19 EPS. American Renal Associates’s revenue was up 12.4% compared to the same quarter last year.

A number of brokerages have recently weighed in on ARA. Zacks Investment Research lowered shares of American Renal Associates from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 23rd. Bank of America lifted their price target on shares of American Renal Associates from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, September 18th. Leerink Swann upgraded shares of American Renal Associates from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $22.00 to $26.00 in a research note on Thursday, August 23rd. Finally, SunTrust Banks reiterated a “buy” rating and set a $25.00 price target on shares of American Renal Associates in a research note on Thursday, August 9th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $22.60.

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in American Renal Associates by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,157,601 shares of the company’s stock worth $25,062,000 after acquiring an additional 44,081 shares in the last quarter. MetLife Investment Advisors LLC acquired a new stake in American Renal Associates during the 3rd quarter worth $230,000. Renaissance Technologies LLC raised its stake in American Renal Associates by 31.7% during the 3rd quarter. Renaissance Technologies LLC now owns 457,800 shares of the company’s stock worth $9,911,000 after acquiring an additional 110,300 shares in the last quarter. JPMorgan Chase & Co. raised its stake in American Renal Associates by 1.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 691,555 shares of the company’s stock worth $14,972,000 after acquiring an additional 12,549 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in American Renal Associates by 12.2% during the 3rd quarter. Franklin Resources Inc. now owns 1,232,805 shares of the company’s stock worth $26,691,000 after purchasing an additional 133,940 shares during the last quarter. Hedge funds and other institutional investors own 94.51% of the company’s stock.

Shares of ARA traded down $0.27 during midday trading on Friday, reaching $16.43. The stock had a trading volume of 102,142 shares, compared to its average volume of 177,479. American Renal Associates has a 1-year low of $13.76 and a 1-year high of $24.07. The firm has a market capitalization of $539.46 million, a price-to-earnings ratio of 26.93, a PEG ratio of 4.54 and a beta of 2.01. The company has a current ratio of 1.03, a quick ratio of 1.00 and a debt-to-equity ratio of 5.48.

About American Renal Associates

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Read More: What is Compound Interest?

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply